{"nctId":"NCT00420199","briefTitle":"A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","startDateStruct":{"date":"2007-05"},"conditions":["Active Rheumatoid Arthritis"],"count":50,"armGroups":[{"label":"Abatacept + Methotrexate (Double-blind period)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Abatacept"]},{"label":"Placebo + Methotrexate (Double-blind period)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Abatacept","otherNames":["(BMS-188667)","Orencia"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Disease activity as defined by a Disease Activity Score 28-C-Reactive Protein (CRP) \\>3.2 or \\>6 swollen and â‰¥6 tender joints and CRP greater than the upper limit of normal\n* At least 1 erosion in hands/wrists or positive anticyclic citrullinated peptides or rheumatoid factor\n* Clinically detectable synovitis of at least 1 wrist/ankle at screening and baseline\n* Participants must have been treated with methotrexate, on a weekly dose of at least 15 mg or a maximum tolerated dose (such as, 10 mg weekly) for at least 3 months before screening. Dose of methotrexate must be stable for at least 28 days prior to the first study dose (Day 1)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)","description":"Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\\*3 wrist regions), indicating most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.48","spread":"2.10"},{"groupId":"OG001","value":"3.52","spread":"2.43"}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Baseline Mean Erosion OMERACT 6 Scores","description":"Bone erosion assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage) according to erosion of the original articular bone (each unit=10% loss of articular bone). The total erosion score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 230. Increasing score=greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.60","spread":"9.41"},{"groupId":"OG001","value":"9.65","spread":"10.11"}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Adjusted Mean Change From Baseline in Erosion OMERACT 6 Scores","description":"Bone erosion assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached hand. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. Total erosion score for hands/wrists is sum of the individual scores for each location. Thus the maximum score per hand/wrist is 230. Increasing score=greater severity. Adjusted change from baseline in erosion score=mean score at Day 113-mean erosion score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"0.43"},{"groupId":"OG001","value":"0.95","spread":"0.45"}]}]}]},{"type":"PRIMARY","title":"Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Planned Analysis Using Non-Parametric ANCOVA","description":"Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\\*3 wrist regions), indicating most severe damage. Change in synovitis=Follow-up synovitis score-baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"1.47"},{"groupId":"OG001","value":"0.52","spread":"1.38"}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Baseline Mean Osteitis OMERACT 6 Scores","description":"Osteitis assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 to 3, indicating involvement of original articular bone. The total score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 23 (total number of anatomic locations) \\* 3 (maximum per joint)=69. Minimum score=0, indicating normal. Increasing score=greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.72","spread":"7.04"},{"groupId":"OG001","value":"8.00","spread":"9.72"}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Adjusted Mean Change From Baseline in Osteitis OMERACT 6 Scores","description":"Osteitis assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached. Each site scored in 1.0 increments, indicating involvement of original articular bone (0=none to 3=severe). Total score for hands/wrists is sum of scores for each location. Maximum score per hand/wrist is 23 (total anatomic locations)\\*3 (maximum score per joint)=69. Minimum score=0(normal). Increasing score=greater severity. Adjusted mean change from baseline in osteitis score=mean score at Day 113-mean score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.94","spread":"0.86"},{"groupId":"OG001","value":"1.54","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Newly Involved Joints in Bone Erosion, Edema/Osteitis, and Synovitis","description":"Bone erosion and osteitis were assessed at a total of 23 anatomic locations according to erosion (for bone erosion) or involvement (for osteitis) of the original articular bone. Synovitis assessed as above-normal post-gadolinium enhancement in 3 wrist regions: distal radioulnar joint, radiocarpal joint, and intercarpal and carpometacarpal joints.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Baseline Mean RAMRIS Scores","description":"RAMRIS score is the sum of its core components: Synovitis Score, Osteitis Score, and Erosion Score. Synovitis scored from 0 (normal) to 9 (maximum distension of synovial cavity). Osteitis scored 0 (normal) to 69 (maximum articular bone involvement). Erosion scored from 0 (normal) to 230 (maximum erosion of articular bone). RAMRIS=Synovial Score + Osteitis Score + Erosion Score. Minimum RAMRIS score=0 (normal), maximum RAMRIS score=308 (severe structural damage). For Synovial Score, Osteitis Score, Erosion Score, and RAMRIS score, increasing number=increasing severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.80","spread":"16.36"},{"groupId":"OG001","value":"21.17","spread":"20.45"}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Adjusted Mean Change From Baseline in RAMRIS Scores","description":"RAMRIS Score=sum of core components: Synovitis (S), Osteitis (O), and Erosion (E) Scores. S scored 0 (none) to 9 (maximum distension of synovial cavity); O scored 0 (none) to 69 (maximum articular bone involvement); E scored 0 (none) to 230 (maximum erosion of articular bone). RAMRIS=S+O+E Scores. RAMRIS minimum score=0 (normal), maximum=308 (severe structural damage). Adjusted change from baseline in RAMRIS=mean RAMRIS at Day 113-mean RAMRIS at baseline. Adjustment based on ANCOVA model: treatment=factor, baseline value=covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.82","spread":"1.13"},{"groupId":"OG001","value":"2.89","spread":"1.18"}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Formation: Osteocalcin and Serum Intact N-terminal Propeptide of Type I Procollagen (PINP)","description":"PINP and osteocalcin are markers of bone formation. Osteocalcin is synthesized by osteoblasts and is associated with osteoblast synthetic activity. Osteoblasts secrete type 1 procollagen, and cleavage of large fragments from the carboxy and amino terminal ends result in formation of mature type 1 collagen and production of PINP fragments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":null},{"groupId":"OG001","value":"4.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.83","spread":null},{"groupId":"OG001","value":"3.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.43","spread":null},{"groupId":"OG001","value":"12.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.62","spread":null},{"groupId":"OG001","value":"-0.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.02","spread":null},{"groupId":"OG001","value":"10.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","spread":null},{"groupId":"OG001","value":"12.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":null},{"groupId":"OG001","value":"10.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.97","spread":null},{"groupId":"OG001","value":"-7.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.18","spread":null},{"groupId":"OG001","value":"7.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":null},{"groupId":"OG001","value":"4.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Destruction (Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen [CTX-I] and Serum Pyridinoline Cross-linked Telopeptide Domain of Type I Collagen [ICTP])","description":"CTX-I and ICTP are biochemical markers of bone resorption or bone degradation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":null},{"groupId":"OG001","value":"-6.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.56","spread":null},{"groupId":"OG001","value":"6.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":null},{"groupId":"OG001","value":"-0.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.47","spread":null},{"groupId":"OG001","value":"4.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.13","spread":null},{"groupId":"OG001","value":"7.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.08","spread":null},{"groupId":"OG001","value":"8.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.94","spread":null},{"groupId":"OG001","value":"15.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.36","spread":null},{"groupId":"OG001","value":"2.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.23","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.29","spread":null},{"groupId":"OG001","value":"11.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Median Percent Change From Baseline in a Systemic Marker of Cartilage Degradation (Creatinine-corrected Urinary Carboxyterminal Crosslinking Telopeptide of Type II Collagen [UCTX2C])","description":"Urinary CTX-II is a biochemical marker of type II collagen breakdown. In participants with early rheumatoid arthritis, increased levels of CTX-II can be predictive of rapid radiographic progression over periods of 1 to 5 years. These markers of cartilage destruction can predict progression of joint damage, independent of clinical and biologic indices of disease activity and baseline joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.51","spread":null},{"groupId":"OG001","value":"5.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.40","spread":null},{"groupId":"OG001","value":"6.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null},{"groupId":"OG001","value":"5.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.83","spread":null},{"groupId":"OG001","value":"9.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.49","spread":null},{"groupId":"OG001","value":"9.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Median Percent Change From Baseline in Systemic Marker of Synovial Tissue Metabolism (Creatinine-corrected Urinary Glucosyl-Galactosyl-Pyridinoline [UGGPC])","description":"Glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) is a specific biochemical marker reflecting the degradation of the synovial tissue membrane. It is a glycosylated derivative of the collagen crosslink pyridinoline, and it is present in significant amounts only in the synovial membrane; it is absent from bone and present in minutes amounts in cartilage and other soft tissues. Increased urinary levels of Glc-Gal-PYD have been found in early and long-standing rheumatoid arthritis, high levels being associated with rapid destruction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.44","spread":null},{"groupId":"OG001","value":"-3.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.83","spread":null},{"groupId":"OG001","value":"-3.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":null},{"groupId":"OG001","value":"5.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":null},{"groupId":"OG001","value":"16.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.16","spread":null},{"groupId":"OG001","value":"-3.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, and AEs Leading to Discontinuation","description":"An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With AEs of Special Interest","description":"An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including serious, opportunistic, and all other infections; autoimmune disorders; neoplasms; acute infusional AEs (prespecified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (prespecified AEs occurring within 24 hours of start of infusion).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Infections/Infestations of Special Interest","description":"Infections/Infestations of Special Interest are AEs and SAEs considered possibly, probably, or certainly related to study treatment, graded according to Common Terminology Criteria for Adverse Events Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death). AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Acute Infusional AEs of Special Interest","description":"Acute infusional AEs are AEs with onset during the first hour after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events ,Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Peri-infusional AEs of Special Interest","description":"Peri-infusional AEs are AEs occurring during the first 24 hours after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events, Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Laboratory Test Results in Hematology Meeting the Criteria for Marked Abnormality","description":"BL=baseline; LLN=lower limit of normal; ULN=upper limit of normal. Marked abnormality criteria: Hemoglobin: \\>3 g/dL decrease from BL. Hematocrit: \\<0.75\\*BL. Erythrocytes: \\<0.75\\*BL. Platelets: \\<0.67\\*LLN/\\>1.5\\*ULN, or if BL \\<LLN, use 0.5\\*BL/\\<100,000 mm\\^3. Leukocytes: \\<0.75\\*LLN/\\>1.25\\*ULN, or if BL\\<LLN, use \\<0.8\\*BL/\\>ULN, or if BL\\>ULN, use \\>1.2\\*BL/\\<LLN. Neutrophils+bands: \\<1.0\\*10\\^3 c/uL. Eosinophils: \\>0.750\\*10\\^3 c/uL. Basophils: \\> 400 mm\\^3. Monocytes: \\>2000 mm\\^3. Lymphocytes: \\<0.750\\*10\\^3 c/uL/\\>7.50\\*10\\^3 c/uL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Laboratory Test Results for Liver and Kidney Function Meeting Criteria for Marked Abnormality","description":"ULN=upper limit of normal; BL=baseline. Marked abnormality criteria: Alkaline phosphatase: \\>2\\*ULN, or if BL\\>ULN, use \\>3\\*BL; aspartate aminotransferase: \\>3\\*ULN, or if BL\\>ULN,use \\>4\\*BL; alanine aminotransferase: \\>3\\*ULN, or if BL\\>ULN, use \\>4\\*BL; G-Glutamyl transferase: \\>2\\*ULN, or if BL\\>ULN, use \\>3\\*BL; Bilirubin: \\>2\\*ULN, or if BL\\>ULN, use \\>4\\*BL; blood urea nitrogen: \\>2\\*BL; creatinine: \\>1.5\\*BL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Laboratory Test Results for Electrolytes Meeting the Criteria for Marked Abnormality","description":"LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Marked abnormality: Sodium: \\<0.95\\*LLN/\\>1.05\\*ULN,or if BL\\<LLN, use 0.95\\*BL or \\>ULN,or if BL\\>ULN, use\\>1.05\\*BL or \\<LLN. Potassium: \\<0.9\\*LLN/\\>1.1\\* ULN,or if BL\\<LLN, use 0.9\\*BL or \\>ULN, or if BL\\>ULN, use\\>1.1\\*BL or \\<LLN. Chloride: \\<0.9\\*LLN/\\>1.1\\*ULN, or if BL\\<LLN, use 0.9\\*BL or \\>ULN, or if BL\\>ULN, use\\>1.1\\*BL or \\<LLN. Calcium: \\<0.8\\*LLN/\\>1.2\\*ULN, or if BL\\<LLN, use 0.75\\*BL or \\>ULN, or if BL\\>ULN, use\\>1.25\\*BL or \\<LLN. Phosphorous: \\<0.75\\*LLN/\\>1.25\\*ULN, or if BL\\<LLN, use 0.67\\*BL or \\>ULN, or if BL\\>ULN, use\\>1.33\\*BL or \\<LLN.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Laboratory Test Results in Other Chemistries and Urinalysis Meeting the Criteria for Marked Abnormality","description":"LLN=lower limit of normal; ULN=upper limit of normal; BL-baseline. Marked abnormality c: serum glucose:\\<65 mg/dL/\\>220 mg/dL; fasting serum glucose: \\<0.8\\* LLN/\\>1.5\\* ULN, or if BL\\<LLN, use 0.8\\*BL or \\>ULN, or if BL\\>ULN, use \\>2.0\\*BL or \\<LLN; total protein: \\<0.9\\*LLN/\\>1.1\\* ULN; albumin: \\<0.9\\*LLN,or if BL\\<LLN, use \\<0.75 BL; uric acid: \\>1.5\\* ULN, or if BL\\>ULN, use \\>2\\*BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, red blood cells, white blood cells):Use â‰¥2 when BL value missing or value â‰¥4,or when predose=0 or 0.5. Use â‰¥3 when predose=1. Use â‰¥4 when predose=2 or 3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Post Hoc Sensitivity Analysis Using Parametric ANCOVA Analysis","description":"Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\\*3 wrist regions), indicating most severe damage. Change in synovitis score=Follow-up synovitis score-baseline synovitis score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.26"},{"groupId":"OG001","value":"0.38","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Double-blind Period:Number of Participants With Significantly Abnormal Changes in Vital Signs","description":"Vital signs, which included blood pressure, heart rate, respiration, and temperature, were monitored predose and 1 hour after start of infusion. Changes in vital signs were determined to be significantly abnormal at the discretion of the investigator but were generally those that either exceeded, or failed to reach, normal parameters. Normal vital sign parameter ranges varied by site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-blind Period: Number of Participants With Positive Antibodies to Abatacept by Electrochemiluminescence (ECL) Assay","description":"On-Rx=on treatment; post-Rx=post treatment. ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction Category=reactivity against constant regions and/or hinge region of human IgG1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["NAUSEA","HEADACHE","DIARRHOEA","NASOPHARYNGITIS","BACK PAIN"]}}}